BioMarin Bumped Up: Fool by Numbers

Recs

1

On Nov. 1, BioMarin Pharmaceutical (Nasdaq: BMRN) released third-quarter earnings for the period ended Sept. 30.

  • Revenues beat the estimates by 11.2%, while EPS topped the consensus estimate with a loss of $0.08.

  • Revenue increases were mainly due to stronger product sales, particularly in Aldurazyme and Naglazyme.

  • Restrained spending and top-line growth let to a significant movement toward profitability.

  • Get our full Foolish Take on BioMarin's latest quarter.

(Figures in thousands, except per-share data)

Income Statement Highlights

Avg. Est.

Q3 2006

Q3 2005

Change

Sales

$19,716

$24,927

$7,579

228.9%

Net Profit*

--

($7,036)

($15,476)

N/A

EPS

($0.12)

($0.08)

($0.21)

N/A

Diluted Shares

--

86,269

71,996

19.8%



Get back to basics with a look at the income statement.

Margin Checkup

Q3 2006

Q3 2005

Change*

Gross Margin

89.52%

97.84%

(8.32)

Operating Margin

(16.51%)

(173.82%)

157.31

Net Margin

(28.23%)

(204.20%)

175.97

*Expressed in percentage points.

Margins are the earnings engine. See how they work.

Balance Sheet Highlights

Assets

Q3 2006

Q3 2005

Change

Cash + ST Invest.

$293.9

$65.9

346%

Accounts Rec.

$13.0

$5.3

145.3%

Inventory

$25.8

$7.7

235.1%


Liabilities

Q3 2006

Q3 2005

Change

Accounts Payable*

$29.2

$22.9

27.5%

Long-Term Debt

$293.1

$214.4

36.7%

*Includes accrued liabilities.

Learn the ways of the balance sheet.

Cash Flow Highlights

A statement of cash flows was not provided.

Find out why Fools always follow the money.

Related Companies:

  • Medarex (Nasdaq: MEDX)
  • Crucell NV (Nasdaq: CRXL)
  • Regeneron Pharmaceuticals (Nasdaq: REGN)
  • ZymoGenetics (Nasdaq: ZGEN)

Related Foolishness:

Get the latest updates from the fast-paced world of biotech, and other spawning grounds for amazing growth stocks, with a free 30-day trial to Motley Fool Rule Breakers.

Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

TD AMERITRADE
more info
ShareBuilder
more info
Power E*Trade

more info
Scottrade
more info
Fool Disclosure

DocumentId: 516952, ~/Articles/ArticleHandler.aspx, 11/11/2009 11:01:21 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

The Must-Read Story on Fool.com
What to Buy? Stocks, Bonds, or Gold?

Related Tickers

11/11/2009 10:44 AM
BMRN $16.77 Up +0.13 +0.78%
BioMarin Pharmaceu… CAPS Rating: ****
CRXL $21.17 Up +0.09 +0.43%
Crucell N.V. (ADR) CAPS Rating: ****
MEDX $16.02 Down +0.00 +0.00%
Medarex, Inc. CAPS Rating: ***
REGN $18.59 Up +2.79 +17.66%
Regeneron Pharmace… CAPS Rating: **
ZGEN $5.97 Up +0.19 +3.29%
ZymoGenetics, Inc. CAPS Rating: ***

Community: Investing Wiki

Term Of The Hour

Covered call: The covered-call strategy of investing involves selling call options on a stock that you also own shares of for the long term. It's a way of trying to make a bit more money out of a stock in terms of generating some income now.

Want to learn more or edit this definition?
Click here to read more!